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Review Article
The effect of phosphodiesterase-5
inhibitors on cerebral blood flow
in humans: A systematic review
Mathilde MH Pauls1,2, Barry Moynihan2,3, Thomas R Barrick1,
Christina Kruuse4, Jeremy B Madigan5, Atticus H Hainsworth1,2
and Jeremy D Isaacs1,2
Abstract
Agents that augment cerebral blood flow (CBF) could be potential treatments for vascular cognitive impairment.
Phosphodiesterase-5 inhibitors are vasodilating drugs established in the treatment of erectile dysfunction (ED) and
pulmonary hypertension. We reviewed published data on the effects of phosphodiesterase-5 inhibitors on CBF in
adult humans. A systematic review according to PRISMA guidelines was performed. Embase, Medline and Cochrane
Library Trials databases were searched. Sixteen studies with 353 participants in total were retrieved. Studies included
healthy volunteers and patients with migraine, ED, type 2 diabetes, stroke, pulmonary hypertension, Becker muscular
dystrophy and subarachnoid haemorrhage. Most studies used middle cerebral artery flow velocity to estimate CBF. Few
studies employed direct measurements of tissue perfusion. Resting CBF velocity was unaffected by phosphodiesterase-5
inhibitors, but cerebrovascular regulation was improved in ED, pulmonary hypertension, diabetes, Becker’s and a group
of healthy volunteers. This evidence suggests that phosphodiesterase-5 inhibitors improve responsiveness of the cerebral
vasculature, particularly in disease states associated with an impaired endothelial dilatory response. This supports the
potential therapeutic use of phosphodiesterase-5 inhibitors in vascular cognitive impairment where CBF is reduced.
Further studies with better resolution of deep CBF are warranted. The review is registered on the PROSPERO database
(registration number CRD42016029668).
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Introduction
Cerebral small vessel disease (SVD) is present in up to
70% of older adults1 and is the commonest cause of
vascular cognitive impairment, which contributes up to
20% of dementia diagnoses.2,3 The overall clinical
impact of SVD is signiﬁcant, aﬀecting cognition,
mood, function and quality of life in older people.4–7
There are no licensed symptomatic treatments for vas-
cular cognitive impairment.3,8 Furthermore there are
no licensed disease modifying agents for SVD, with
current interventions limited to controlling risk factors
for vascular disease in general.3,4,8
Cognition declines over time as SVD advances.2,9–11
Cerebral blood ﬂow (CBF) is reduced in SVD in grey and
white matter, with particularly severe changes in subcor-
tical areas.1,12–14 Whether reduced CBF is a cause or a
consequence of SVD is unclear. This issue is complex to
resolve because standard magnetic resonance imaging
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(MRI) sequences may not be suﬃciently sensitive to
detect the earliest pathological changes in SVD.13 15
However, reduced CBF may occur prior to the onset of
clinical symptoms of Alzheimer’s disease (AD),16 and is
the earliest observed neurological abnormality in mouse
models of AD.17 The mechanisms by which reduced CBF
might accelerate SVD pathogenesis are unclear, but
reduced protein synthesis is a well-described eﬀect of
mild degrees of cerebral ischaemia.18
CBF regulation is dependent on intact endothelial
and myocyte function in small penetrating arteries,
which facilitates increased regional blood ﬂow in
response to demand, such as during cognitive activity.17
This process can be termed cerebrovascular regulation
(CVR). Impaired CVR may be associated with vascular
risk factors and vascular disease in general.19,20
However, impairment of endothelium-dependent CVR
is postulated to be a speciﬁc pathological feature of
SVD.21–24 Although data are limited there is some evi-
dence that impaired CVR correlates with the burden of
white matter hyperintensities, a key radiological marker
of SVD.25 Similarly, haemodynamic pulsatility, a meas-
ure of vessel stiﬀening, has also been shown to strongly
correlate with the degree of leukoaraiosis.26 Improving
CBF and CVR by augmenting endothelial-myocyte sig-
nalling (and thus improving function of the neurovas-
cular unit) therefore has potential as both symptomatic
and disease-modifying treatment for SVD.8
Phosphodiesterase-5 (PDE5) inhibitors (PDE5i) are
used in the treatment of pulmonary hypertension (PH)
and erectile dysfunction (ED). Inhibition of PDE5
reduces breakdown of cyclic guanosine monophosphate
(cGMP), leading to vascular smooth muscle relaxation
in small blood vessels, as for example in the treatment
of ED where PDE5i delay de-tumescence.27 In PH
PDE5 is more active and expressed more abundantly
in the pulmonary vasculature.28,29 PDE5i reduce this
heightened activity (sildenaﬁl increasing cGMP levels
5- to 10-fold) leading to vasodilation. In PH there
appear to be further downstream eﬀects, PDE5i leading
to reduced DNA synthesis in myocytes and reduced
smooth muscle proliferation.29
PDE5 mRNA and protein are expressed in brain
tissue of humans and experimental animals.30–33
Western blot detects PDE5 in both meningeal and
larger cerebral arteries of experimental rodents and
human participants34,35 and immunohistochemical label-
ling shows that PDE5 is present in smooth muscle cells of
small arterial vessels.36 PDE5 activity in SVD has not
been reported. This raises the question whether PDE5i
could augment vasodilation of cerebral blood vessels,
and hence increase CBF and/or restore CVR in SVD.
The aim of this review is to synthesise published data
from human studies on the eﬀects of PDE5i on CBF
and CVR in adults.
Materials and methods
Protocol: PRISMA guidelines were followed (please see
the PRISMA checklist online Supplement).
Eligibility criteria and study selection: randomized
clinical trials and observational studies investigating
the eﬀects of PDE5i on CBF in adult humans were
considered for inclusion. Abstracts were considered if
data were presented. All imaging modalities for directly
or indirectly measuring CBF and CVR were included.
Only papers available in English were included.
Publications were excluded if they had no adult
human data, did not use selective PDE5i, or had no
data on measurements of CBF. Case reports presenting
data from single subjects were excluded. For excluded
studies please see Supplement Table 1.
Information sources: (1) Embase, Medline and the
Cochrane Library database searches were performed
initially up to November 2016, and then repeated to
check for new publications on 4 August 2017. Results
were reviewed independently by MMHP and JDI. (2)
Reference lists of all included studies, as well as of rele-
vant non-eligible studies were checked.
Search strategies can be found in the online
Supplement SII.
Data extracted from individual studies were: partici-
pant characteristics, presence or absence of a control
group, intervention (drug name, dose, duration and
route of administration; any comparisons between rest-
ing state and other conditions), assessment modalities
and outcomes.
Risk of bias in individual studies was assessed using
the Cochrane bias assessment tool.
A qualitative narrative synthesis was performed
because the very heterogeneous studies and data were
unsuitable for meta-analysis.
Results
Sixteen studies with a total of 353 participants were
included in the review (for PRISMA diagram see
Figure 1). Summaries of the included papers are given
in Table 1. Regarding the included studies: six studies
were double blind randomised controlled studies
(n¼ 103 participants).37–42 One was a randomised
non-blinded study (n¼ 30), the two participant groups
receiving two diﬀerent medication protocols.43 Two
studies with a total of 68 participants were controlled
but not randomised or blinded.44,45 Seven observa-
tional studies with a total of 152 participants were
included.46–52 Details of risk of bias are displayed in
Table 2.
In addition to eﬀects on CBF, we assessed papers
for other reported eﬀects of PDE5i. No cognitive
assessments were performed in any of the trials, but
no detrimental eﬀects on cognition were reported.
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One trial in subarachnoid haemorrhage (SAH) reported
a clinical improvement in one patient with resolution of
pronator drift after administration of PDE5i.50
Reported side eﬀects were consistent with the known
eﬀects of PDE5i, including headache, ﬂushing and
visual disturbance.49
A summary of the outcome measures used in the
various studies is shown in Table 3.
Healthy individuals
Four studies investigated the eﬀect of sildenaﬁl on
CBF in healthy individuals. In two, sildenaﬁl was
compared to placebo in a double blind crossover
design. The measure of CBF was mean blood ﬂow
velocity in the middle cerebral artery (VMCA) in one
study,37 and an average of maximal velocities in the
other,39 both determined by transcranial doppler ima-
ging (TCD). Neither trial found changes in resting
VMCA. In one of these studies
39 single-photon emis-
sion computed tomography (SPECT) imaging with
Xenon 133 inhalation was also used to assess regional
CBF at rest, with no diﬀerence between sildenaﬁl and
placebo. In a later study using functional magnetic
resonance imaging (fMRI), sildenaﬁl did not aﬀect
changes in CVR triggered by hypercapnia and visual
stimuli.47
In contrast, a study with 14 healthy male volunteers
found that 1 h after sildenaﬁl (100mg) CVR was
improved, in that VMCA decreases associated with
hyperventilation were attenuated. Estimated cerebro-
vascular resistance (calculated as mean blood pressure
divided by mean VMCA) was reduced in both the hyper-
capnia and hyperventilation (i.e. hypocapnia)
conditions.52
Migraine
A double blind crossover trial40 investigated the eﬀect
of sildenaﬁl on resting VMCA as well as resting global
and regional CBF (using SPECT) in 12 migraineurs.
Radial and temporal artery diameters were also mea-
sured. Ten subjects experienced a migrainous headache
after sildenaﬁl, and only two subjects after placebo.
955 records identified through 
database searching (Embase, 
Medline and Cochrane searches 
and repeats thereof) 
Two additional records 
identified through reference 
searches  
957 records screened 
931 records excluded: 
duplicates, reviews, 
not relevant (e.g. non 
cerebral, not PDE5, 
animal studies)   
26 articles assessed for 
eligibility 
16 studies included in 
qualitative synthesis  
10 articles excluded, 
with reasons: case 
reports, no CBF results 
reported,
Dipyridamole, 
neonates 
Figure 1. PRISMA flow diagram;
PDE5: phosphodiesterase 5; CBF: cerebral blood flow.
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Table 3. Summary of outcome measures used in each included study – (indicated by ˇ).
Study Summary
MCA
velocity
Cerebrovascular
reactivity pCO2 SPECT Other
Al-Amran et al.44 N¼ 18 diabetics
N¼ 17 controls
ˇ ˇ (TCD)
Arnavaz et al.37 N¼ 6 ˇ
Chan et al.46 N¼ 10 ˇ ˇ regional O2
Saturation
Dhar et al.51 N¼ 6 ˇ PET imaging
Diomedi et al.38 N¼ 14 sildenafil
N¼ 14 placebo
ˇ ˇ (TCD) ˇ
Jahshan et al.52 N¼ 14 ˇ ˇ (TCD) ˇ
Kruuse et al.39 N¼ 12 ˇ ˇ
Kruuse et al.40 N¼ 12 (cross-over) ˇ ˇ ˇ
Kruuse et al.47 N¼ 13 ˇ (fMRI) ˇ
Lindberg et al.42 N¼ 12 ˇ (fMRI) ˇ ˇ MRI (ASL, MRA
and MCA dimension)
Lorberboym et al.48 N¼ 25 ˇ
Lorberboym et al.43 N¼ 30 ˇ
Mukherjee et al.49 N¼ 72 ˇ
Rosengarten et al.45 N¼ 33 ˇ ˇ (TCD) ˇ ˇ right heart
catheterization
Van Osta et al.41 N¼ 35 ˇ ˇ (TCD) ˇ
Washington et al.50 N¼ 12 ˇ cerebral
angiography
N¼ 257 N¼ 170 N¼ 147 N¼ 79
Table 2. Assessment of risk of bias using Cochrane risk of bias assessment tool (low risk versus high risk versus unclear), max. score
8 (higher score meaning a lower risk of bias).
Study
Score
(out of 8)
Random
sequence
generation
Allocation
concealment
Blinding of
participants
Blinding of
study
personnel
Assessor
blinding
Incomplete
outcome
data
Selective
reporting
Other
bias
Al-Amran et al.44 3 High High High High High Low Low Low
Arnavaz et al.37 8 Low Low Low Low Low Low Low Low
Chan et al.46 2 High High High High High Low Low High
Dhar et al.51 2 High High High High High Low Low High
Diomedi et al.38 8 Low Low Low Low Low Low Low Low
Jahshan et al.52 3 High High High High High Low Low Low
Kruuse et al.39 8 Low Low Low Low Low Low Low Low
Kruuse et al.40 8 Low Low Low Low Low Low Low Low
Kruuse et al.47 3 High High High High High Low Low Low
Lindberg et al.42 8 Low Low Low Low Low Low Low Low
Lorberboym et al.48 1 High High High High High Unclear High Low
Lorberboym et al.43 3 Unclear High High High High Low Low Low
Mukherjee et al.49 2 High High High High High Low Unclear Low
Rosengarten et al.45 2 High High High High High Low Low High
Van Osta et al.41 8 Low Low Low Low Low Low Low Low
Washington et al.50 2 High High high High Unclear Low Low High
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There were no changes in global or regional CBF,
VMCA, or in radial or temporal artery diameter.
High altitude
In a double blind trial 35 healthy individuals were ran-
domly allocated to tadalaﬁl 10mg twice daily, dexa-
methasone 8mg twice daily or placebo.41 VMCA and an
Acute Mountain Sickness (AMS) score were measured
at an altitude of 490m and approximately 20h after a
two-day ascent to 4559m. The cerebral autoregulation
index (ARI) was used to assess CVR. ARI was calcu-
lated from the rate of restoration of VMCA following an
acute spell of hypotension induced by the sudden release
of bilateral thigh cuﬀs inﬂated to 30mmHg above sys-
tolic blood pressure for 3min.53 Neither tadalaﬁl nor
dexamethasone had a signiﬁcant eﬀect on VMCA or
ARI. AMS score improved with dexamethasone and
tended to be better with tadalaﬁl than placebo.
In an uncontrolled study (n¼ 10) sildenaﬁl 50mg was
given one and three days after rapid ascent to 3480m.46
Measurements were taken prior to dosing and at 1 and
2h post-dosing on each day. On day one, systemic
oxygen saturation (SaO2) and cerebral oxygenation
increased after sildenaﬁl, with unchanged VMCA and
end-tidal partial pressure of carbon dioxide (pCO2).
On day three, systemic SaO2 did not change after
sildenaﬁl, but cerebral oxygenation again increased des-
pite a reduction in VMCA.
Diabetes mellitus
One study investigated 18 subjects with type two dia-
betes mellitus and 17 age-matched healthy controls.44
Subjects with a history of cerebrovascular disease were
excluded. VMCA, cerebrovascular reactivity assessed
using breath holding54 and full range of vasodilation
(FVD) were measured 50min after a single dose of
sildenaﬁl (50mg). FVD was derived from a comparison
between breath holding (leading to increased pCO2 and
vasodilation, the parameters commonly used to assess
cerebrovascular reactivity) and hyperventilation
(leading to decreased pCO2 and vasoconstriction);
54
(see Table 4 for formulae for cerebrovascular reactivity
and FVD). VMCA was signiﬁcantly increased by breath
holding and decreased by hyperventilation in both the
diabetic and healthy control groups, but the response
was attenuated in those with diabetes. While these
responses did not vary following sildenaﬁl administra-
tion in the healthy control group, the diabetic group
showed signiﬁcant improvements in cerebrovascular
reactivity and FVD with sildenaﬁl.
ED without known cerebrovascular disease
One double-blind randomised controlled trial com-
pared sildenaﬁl (50mg) with placebo38 in 28 men with
ED but no history of cerebrovascular disease. The
measure of CVR used was cerebrovascular reactivity
(VMCA response to breath holding). No diﬀerence was
found in resting VMCA 1 h post-dosing with sildenaﬁl
compared to placebo. However, sildenaﬁl signiﬁcantly
improved cerebrovascular reactivity.
ED with stroke and/or SVD
Two studies investigated the eﬀects of PDE5i on CBF
in patients with cerebrovascular disease and ED.43,48
Both used pre- and post-dose SPECT imaging to
assess regional CBF. The initial study48 enrolled 25
male patients with ED, of whom 12 had a history of
ischaemic stroke 1–5 years prior to study participation.
Among the other 13 participants, eight had non-
territorial focal areas of diminished CBF on baseline
SPECT, and ﬁve had diﬀuse CBF abnormalities sug-
gestive of SVD. The extent and exact location of white
matter intensity lesions were not reported. One hour
after oral administration of sildenaﬁl (50mg) the
post-stroke group showed more areas with relatively
diminished perfusion, and fewer areas of relatively
increased perfusion, compared to non-stroke patients,
although there was variation between subjects within
the group. It was not possible to identify a clear pattern
from the Brodman areas that were listed as showing a
signiﬁcant diﬀerence (not localised to one hemisphere
or a particular region).
In the second study43 all participants had ED and a
history of large vessel ischaemic (n¼ 6 right MCA,
n¼ 9 left MCA) or small vessel ischaemic stroke
(n¼ 15; all participants had more than one lesion)
that had occurred 3–36 months prior to the study.
Lesion volumes were not reported. Participants were
randomised to either single dose tadalaﬁl (20mg) or
daily dosing of tadalaﬁl (5mg) for seven days. SPECT
was performed at baseline and 6 h after the ﬁnal
(or single) dose.
Reduced relative CBF was found in the stroke-
aﬀected hemisphere as a whole versus the unaﬀected
hemisphere after tadalaﬁl, in both treatment arms,
Table 4. Cerebrovascular reactivity and full range of vasodila-
tion (FVD) formulae.
Parameter Formula
Cerebrovascular
reactivity
(VMCA hypercapnia  VMCA baseline) /
VMCA baseline
FVD 100 [VMCA hypercapnia 
VMCA hypocapnia]/ VMCA rest
VMCA: middle cerebral artery velocity.
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particularly in the zones bordering the infarct.
However, smaller cortical and subcortical areas
showed mixed eﬀects (with areas of increased and
decreased ﬂow on either side), with no clear region or
side-speciﬁc pattern. No signiﬁcant diﬀerence was
found between the two stroke groups (small vessel
versus large vessel) or the two dosing regimens.
Subarachnoid haemorrhage
Three uncontrolled studies investigated the eﬀects
of sildenaﬁl during the acute phase of SAH.49–51 One
study49 enrolled 72 patients with vasospasm refractory
to 24 h of hypertension, hypervolaemia and haemodilu-
tion (HHH) therapy. All patients had had their aneur-
ysms surgically secured and had received nimodipine.
Following administration of 100–150mg of intravenous
sildenaﬁl every 4 h (for 2–7 days) eight showed sus-
tained (>48 h) reduction in VMCA (>40 cm/s), and ﬁve
had intermittent reductions.
In another study50 12 patients with angiogram
proven vasospasm received intravenous sildenaﬁl
(10–30mg). Angiography was repeated 30min after
infusion. Eight patients had an improvement in
vasospasm.
In a further study 15O2-positron emission
tomography (PET) imaging was performed pre- and
post-intravenous sildenaﬁl in six patients with digital
subtraction angiography proven SAH.51 No changes
in regional or global CBF were found after sildenaﬁl.
None of these studies had a control group or control
condition.
Pulmonary hypertension
In 11 adults with severe PH, inhaled iloprost and 50mg
oral sildenaﬁl were administered consecutively (with a
washout period).45 Flow velocity of the posterior cere-
bral artery (VPCA) was recorded at baseline (where it
was signiﬁcantly lower in those with PH versus con-
trols), and in response to a visual stimulation paradigm.
Pulmonary arterial pressure and systemic vascular
resistance were also assessed. The 22 healthy control
participants underwent the visual stimulation and
VPCA measurements but were not given the study medi-
cation and did not have right heart catheterisation. In
subjects with PH both agents reduced pulmonary and
vascular resistance parameters. The attenuation param-
eter (which represents dampening of ﬂow variation due
to the vessel wall) and the time rate parameter (which
represents the initial steepness of CBF velocity increase)
were also assessed. Sildenaﬁl administration was asso-
ciated with normalization of both of these in PH.
In contrast, iloprost slightly worsened the time rate
parameter.
Becker muscular dystrophy (BMD)
In BMD the dystrophin protein is absent or truncated
leading to loss of neuronal nitric oxide synthase
(nNOS) and nitric oxide (NO) production, causing
functional ischaemia in skeletal muscle, and possibly
also in cerebral vascular myocytes.42 A randomised
double blind cross-over trial of 12 participants with
BMD compared the eﬀect of sildenaﬁl with placebo
in a four-week treatment block.
CVR in response to sensory stimulation was examined
using blood oxygenation-level dependent (BOLD) func-
tional MRI. Compared to placebo, sildenaﬁl signiﬁcantly
increased BOLD signal in the somatosensory cortex in
response to median nerve stimulation. Increased BOLD
response was also observed in the visual cortex following
a ﬂickering checkerboard stimulus.
MCA circumference and CO2 reactivity, measured
using MR phase contrast mapping and MR angiog-
raphy, were unaﬀected by sildenaﬁl.
Discussion
Summary of findings
In the studies retrieved resting CBF was not aﬀected by
PDE5i in health or disease states37–42,44,45,51 with the
possible exception of SAH.49,50 In contrast, CVR in
states of acute challenge, such as hyperventilation or
stimulatory tasks, was improved by PDE5i. This was
observed in clinical conditions associated with impaired
endothelial vasodilatory responses,38,42,44,45 and also in
one study of healthy volunteers.52
Potential mechanisms
Vascular smooth muscle tone regulation is complex, with
inputs from neurons, glia, interneurons and perivascular
nerves.55,56 Contractile messengers include the sympa-
thetic neurotransmitters norepinephrine and neuropep-
tide Y. Sympathetic stimulation via beta-adrenoceptors
augments L-type calcium channel activity. Relaxant
mediators include the parasympathetic transmitter
acetylcholine, vasoactive intestinal peptide, calcitonin
gene-related peptide and substance P. Many messengers
converge on a key signalling pathway: endothelial
derived NO.55,56 NO activates soluble guanylate cyclase
in myocytes, which converts guanosine triphosphate to
cGMP. As cGMP concentration increases, smooth
muscle tone is reduced and the vessel dilates.55–57
Altered NO-cGMP signalling has been shown to be
a feature of PH29 and ED,27 and is augmented in both
conditions by PDE5i treatment. A similar mechanism
may also apply to the cerebral circulation. This is sup-
ported by the fact that endothelial cells have an
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important role in CBF regulation.22,25 Vessel wall
morphology and function are aﬀected in SVD.22,58,59
The PDE5i-mediated improvement in CVR noted
here, in individuals with diseases aﬀecting vascular
function38,44,45,48 may reﬂect augmented responsiveness
of the endothelium and neurovascular unit to local
metabolic or neurogenic stimuli.
The study investigating BMD42 supports this theory,
describing ‘functional ischaemia’ due to reduced func-
tion of nNOS, rather than endothelial NOS (eNOS),
and showing augmented responses to stimuli following
treatment with sildenaﬁl (see below).42 Although a dif-
ferent subtype of NOS is implicated, these ﬁndings
support a role for the NO-cGMP signalling pathway
in CVR.
In PH, where endothelial PDE5 is expressed more
abundantly than in healthy lung,29,60 the vasodilatory
eﬀects of PDE5i (leading to reductions in pulmonary
arterial pressure) are well-described.27,61–64
Furthermore, PDE5i attenuate vascular remodelling
and right ventricular hypertrophy, as well as improving
functional status in PH.29,60,65,66
It is interesting that a similar response was found in
one study in healthy males assessed by TCD in response
to hypercapnia and hypocapnia,52 but not in a study of
healthy females using fMRI,47 or in the healthy control
group in another study.44 Diﬀerences in imaging mod-
alities and diﬀerent sildenaﬁl doses (100mg in the ﬁrst
two of these studies, 50mg in the third) may explain
these divergent ﬁndings. The eﬀectiveness of the hyper-
capnic stimulus may have varied between studies; only
Jahshan et al.53 conﬁrmed a rise in pCO2 and were also
the only authors to report an eﬀect of PDE5i on CVR
in healthy volunteers. Furthermore, all three of these
studies had small sample sizes.
SVD is also associated with proximal vessel stiﬀness
and pulsatility; increased MCA pulsatility has been
proposed to damage the microvasculature by transmit-
ting higher pressure diﬀerences between systole and dia-
stole to the cerebral small arteries.26 Of the studies here,
only one investigated haemodynamic pulsatility, using
PCA attenuation parameter (a measure of dampening
due to vessel wall attenuation) and time rate parameter
(representing the initial steepness of blood velocity
increase).45 Both measures were improved by sildenaﬁl
in participants with PH. This raises the question
whether PDE5i might delay the progression of SVD
by mitigating the deleterious eﬀects of raised large
artery pulsatility on the small vessels.
The lack of change in basal CBF following PDE5i,
in the papers retrieved here, may reﬂect the absence of
a stimulus. Another explanation is that the techniques
used were insuﬃciently sensitive to detect modest
changes in resting CBF in relevant brain regions (sub-
cortical nuclei and white matter).
Among the included studies, 10 used TCD to meas-
ure CBF velocity in the middle cerebral artery
(VMCA
37–41,44,46,49,52) or posterior cerebral artery
(VPCA
45). Although TCD is non-invasive, aﬀordable,
portable and readily repeatable, and gives ‘real time’
readings of ﬂow velocity, it has important limitations.
TCD assesses ﬂow velocity in one large vessel only, and
thus only indirectly the overall blood supply to the
brain as a whole. Importantly, it does not report on
the smaller, deep brain vessels implicated in SVD, and
the distribution of ﬂow across these. Further, it is likely
incorrect to assume that constant VMCA implies no
change in blood volume delivered to the brain.
Speciﬁcally, this inference must assume a constant
diameter of the vessel measured. In contrast, in patients
with SAH, decreased VMCA is interpreted as MCA dila-
tation reﬂecting greater global CBF.49,50 Even very
small changes in vessel diameter imply very signiﬁcant
changes in ﬂow at a given velocity as vessel resistance is
related to vessel radius to the power of four. Although
accurate measurement of vessel diameter would thus be
key to determining blood ﬂow, none of the TCD studies
retrieved here directly measured MCA diameter; one
study measured radial and temporal artery diameter
(both unchanged), and calculated MCA diameter
from SPECT assessment of CBF and VMCA.
40 MCA
diameter assessed by magnetic resonance angiography
(MRA) in the BMD study was unchanged,42 and
increased in some participants in one of the SAH
studies, where it was measured by digital subtraction
angiography.50 In light of these reports, we believe that
assumptions regarding MCA diameter should be
viewed with caution.
Measurement of CBF can also be performed using
SPECT, PET, fMRI and arterial spin labelling (ASL)
MRI, which allow resolution of regional CBF.
The studies using hexamethylpropyleneamineoxime
(HMPAO) or Xenon SPECT.39,40 functional47 and
cross-sectional perfusion MRI42 found no change in
regional and global CBF at rest following PDE5i treat-
ment in healthy individuals, migraineurs or BMD.
After stimulation, the BMD patients showed an
increase in regional response with sildenaﬁl (measured
using BOLD fMRI).42 In two studies using HMPAO
SPECT in individuals with prior stroke, a relative
reduction in regional CBF in and around the stroke
lesion was reported, with increase in some other brain
areas.43,48 The authors ascribe this to post-stroke dys-
function of cerebral auto-regulation, leading to a ‘steal
phenomenon’ whereby healthy brain is able to achieve
a greater vasodilatory response at the expense of ischae-
mic areas.67 However, infarcted areas will not regain
blood ﬂow. Around the infarct, there may also be
areas of oligaemia, which have only limited supply
from collateral vessels.68–70 Underlying pathology and
Pauls et al. 199
mechanisms in large vessel strokes are diﬀerent to those
in SVD, so these ﬁndings may not be generalisable.
Furthermore, measurements of reduction in relative
ﬂow in areas immediately adjacent to infarct areas
may also be due to sub-optimal spatial resolution of
SPECT, with voxels overlapping the infarcted area,
i.e. partial volume eﬀect.71,72
It is not currently known whether changes in CVR
reviewed here aﬀect cognitive performance, or alter dis-
ease progression in SVD.
In vascular cognitive impairment there is a lack of
consensus regarding disease classiﬁcation and diagnos-
tic criteria, and the exact relation between pathology
and cognition has not been determined. Patient
groups in trials are thus often heterogeneous (including
‘pure’ SVD, lacunar infarcts in ‘strategic’ positions,
larger infarcts, bleeds, and amyloid-related pathology)
so that it has been diﬃcult to identify therapeutic
targets and treatments.3,4 An attempt to reduce cogni-
tive decline in SVD through blood pressure control and
antiplatelet treatment was negative in a phase III study
monitoring participants for a mean of three years.73
Pre-clinical studies of the eﬀects of PDE5i in cere-
brovascular disease are limited by the lack of a robust
animal model of SVD.74 However, studies of PDE5i in
animal models of neurodegeneration have shown pro-
mising results. A study using sildenaﬁl found
improved memory task performance in a mouse
model of AD.75 In a similar mouse model tadalaﬁl
improved water maze performance and reduced Tau
phosphorylation after 12 weeks of treatment.76 Object
recognition task performance was also improved by
PDE5i in male Wistar rats.77 Acute stroke studies in
rodents found improved outcome with PDE5i, appar-
ently due to neurorepair.78–81
Studies of the eﬀects of PDE5i on cognition in
humans are limited. A study of sildenaﬁl in 10 healthy
males found enhanced event-related potentials, but no
changes in auditory attention and word recognition.82
In another study of six healthy participants sildenaﬁl
enhanced performance in a simple reaction time test,
but not on other measures (including short term
memory and divided attention).83
Beneﬁcial neurorestorative and functional eﬀects of
sildenaﬁl have been observed in two case reports. In a
subject with a history of occipital infarcts, visual ﬁeld
defects improved following sildenaﬁl treatment,84 and
in an individual with spastic quadriplegia, mild motor
restoration was found after administration of sildenaﬁl
(the details of this are not further speciﬁed).85
Whether the cognitive eﬀects observed in the two
single-dose studies in healthy individuals82,83 can be
sustained with longer-term administration is unclear.
However, the case reports of single subjects with disease
states (spastic quadriplegia and stroke) reported
improvements in symptoms lasting seven85 to over 12
months84 in motor and visual symptoms, respectively.
Limitations
The review is limited by the relative paucity of research
studies and variability in data quality. Of the included
studies, only six were double blind randomised con-
trolled trials (three cross-over trials, three with a control
group) with a total of 103 participants.37–42 Individually
these trials had small sample sizes, ranging from six37 to
35 (divided into three treatment and control groups).41
None of the remaining studies were blinded and only a
further two had control groups.44,45 Results should thus
be interpreted with caution.
The participant groups in the studies included here
are very heterogeneous with a variety of brain and/or
systemic pathologies and hence potentially disparate
disease mechanisms. Protocols of intervention, PDE5i
used, route of administration and outcome measures
diﬀered between studies, with a range of techniques
used to measure CBF.
It should also be noted that most of the retrieved
studies only assessed acute (often single) dosing of
PDE5i. Exceptions to this are the BMD study, where
sildenaﬁl was given for four weeks prior to assess-
ment,42 the stroke and ED study comparing once
only tadalaﬁl with a seven day regimen43 and one of
the altitude trials, where PDE5i was given for about
four days.46 Nevertheless, none of the interventional
studies investigated periods longer than a number of
weeks. One of the altitude studies, however, showed
attenuation of some of the observed changes on day
three versus day one.46 This raises the question whether
any short-term eﬀects on CVR observed will be main-
tained with longer-term administration.
Whether or not PDE5i had been used prior to study
intervention by participants is not reported, particu-
larly in the ED38,43,48 and PH studies,45 where this
may be expected (the study in PH included participants
‘using or not using sildenaﬁl’48). Only three studies
explicitly state that subjects were not using40,47 or
were not previous users50 of PDE5i.
Across all studies, of the 353 participants only 53
were female (with one of the SAH studies not specifying
gender49), thus females are signiﬁcantly under-repre-
sented, particularly in the studies investigating disease
groups. Due to these factors comparison across studies
is imperfect and ﬁndings cannot easily be generalised.
Conclusions
Our systematic review of the literature suggests that
PDE5i aﬀect CBF in certain clinical conditions.
Measures of CVR, but not basal CBF, are improved
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by PDE5i especially in disorders characterised by an
impaired endothelial dilatory response. This may be
because deﬁcient NO-mediated signalling has dispro-
portionate eﬀects on brain microvascular responsive-
ness compared to the resting state. Although PDE5i
did not produce increases in resting CBF that were
detectable with middle cerebral artery insonation, a
possible action on resting CBF at the level of the
small arterioles remains untested.
Future studies using high resolution, blood-ﬂow spe-
ciﬁc cross-sectional imaging techniques as surrogates of
deep CBF measurements (e.g. ASL MRI86) are war-
ranted to explore eﬀects of PDE5i at the arteriolar
level. Future studies should also test whether PDE5i
mediated vascular changes are correlated with cognitive
function, using tools that assess appropriate cognitive
features such as attention, information processing
speed and executive function, which are particularly
aﬀected in SVD.3,4,9,87
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